170729-73-4Relevant articles and documents
Structural optimization affording 2-(R)-(1-(R)-3,5- bis(trifluoromethyl)phenylethoxy)-3'-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4- triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist
Hale, Jeffrey J.,Mills, Sander G.,MacCoss, Malcolm,Finke, Paul E.,Cascieri, Margaret A.,Sadowski, Sharon,Ber, Elzbieta,Chicchi, Gary G.,Kurtz, Marc,Metzger, Joseph,Eiermann, George,Tsou, Nancy N.,Tattersall, F. David,Rupniak, Nadia M. J.,Williams, Angela R.,Rycroft, Wayne,Hargreaves, Richard,MacIntyre, D. Euan
, p. 4607 - 4614 (2007/10/03)
Structural modifications requiring novel synthetic chemistry were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist 4, and this resulted in the discovery of 2-(R)-(1-(R)-3,5- bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phe